In a short period of 18 months, the company’s preclinical portfolio shows that NovaLead's technology enabled discovery approach is sustainably delivering viable, well differentiated, products covering a wide therapeutic spectrum. NovaLead's growth strategy has evolved from this strength.
The pivot of NovaLead's strategy is the belief that new products can be brought to the market faster through partnerships / collaborations among companies having complimentary skills and the infrastructure. Employing this model, NovaLead's primary goal is to build a cash-generative, profitable and sustainable pharmaceutical business around two types of collaborations:
For progressing NovaLead's candidates
The company intends to pursue Oncologic and other unmet needs in-house through a combination of novel chemical entities and new indications for FDA approved generic drugs. At varying stages of clinical investigation, NovaLead will seek partnerships with pharmaceutical companies that have the necessary infrastructures to develop and market drugs. The company expects that its lead compound VLI27 in pancreatic cancer (NCE) and Diabetic wound (New indication for an approved drug) will be the first two candidates for partnering. Know more
Participating in external programs
In-house research at NovaLead has validated immense potential of NovaLead's capabilities in reliable technology enabled therapeutic profiling of a chemical entity across a wide spectrum of therapeutic targets to identify new product opportunities. With this proven capability, NovaLead will seek collaborations with pharmaceutical and biopharmaceutical companies to help in their eternal quest for improving research productivity through multiple strategies. Know more
